FilingReader Intelligence
Betta Pharmaceuticals' ensartinib shows positive lung cancer trial results
August 24, 2025 at 11:59 PM UTC•By FilingReader AI
Betta Pharmaceuticals announced positive interim results for ensartinib in ALK-positive non-small cell lung cancer adjuvant therapy trials, meeting the primary endpoint with significant statistical and clinical benefits.
The company is preparing to submit a New Drug Application for this new indication.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300558•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Betta Pharmaceuticals publishes news
Free account required • Unsubscribe anytime